News

Dr. David J. Bearss Recipient of 2023 Governor's Medal of Science Award

Empowered Patient Podcast episode featuring David J. Bearss

Targeting a Regulator of Inflammation to Treat Alzheimer's Disease

Biopharma Execs Adopt Creative Mindset at BIO CEO

Halia Therapeutics Appoints Anya Neidig, MSN, RN, as Director of Clinical Operations

Halia Therapeutics to Present at the 2023 BIO CEO & Investor Conference

Amgen’s Margit Janát-Amsbury named Halia CMO

'Perfect time': SIGA's CEO on retirement; Juvenescence woos GSK vet to lead anti-aging play

Chutes & Ladders—David Kessler resigns from the Biden admin...unofficial end of Operation Warp Speed

Up and down the ladder: The latest comings and goings

Halia Therapeutics Appoints Former Amgen Executive, Margit M. Janát-Amsbury, MD, Ph.D., as CMO

Appointments and advancements for Jan. 19, 2023

Halia Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Biotech CFOs sharpen financing tactics for lean times

Halia Therapeutics Presents at 4th Inflammasome Therapeutics Summit

BioUtah Announces Halia CEO David Bearss Ph.D. as their 2022 Entrepreneur of the Year Award Winner

Halia Therapeutics Promotes Targeting the NLRP3 Inflammasome for Alzheimer's Disease Treatment

Halia Therapeutics Announces Poster Presentation at Alzheimer’s Association Int'l Conference 2022

Halia Therapeutics Announces First Participant Dosed in Phase 1 Clinical Study of HT-6184

Here’s how Halia Therapeutics aims to curb Alzheimer’s—and more